CD38 and neuroblastoma: To support the contention that the CD38 adenosinergic pathway was prevalent in neuroblastoma, we performed in silico analysis of CD38 and CD73 expression levels in neuroblastoma samples from 786 patients in the Cangelosi neuroblastoma database.52 As shown in Fig. 3, there is a strong correlation between expression of CD38 and CD73 (p = 5.3 × 10−27) and between CD38 and CD203a (p = 10 × 10−8), suggesting that this pathway is actively producing ADO, leading to immunosuppression.